|
42 Companies |
|
55 Products |
|
55 Products |
|
62 Mechanisms of Action |
|
3 Trials |
|
315 News |
|
| «1234567» |
- |||| Allovectin-7 (velimogene aliplasmid) / AnGes MG, Fresh Tracks Therap
Trial completion, Gene therapy, Metastases: Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=78, Completed, Sponsor: Vical
No longer recruiting --> Completed
- | Trial completion: Photodynamic Therapy in Treating Patients With Skin Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=180, Completed, Sponsor: Roswell Park Cancer Institute
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Photodynamic Therapy in Treating Patients With Skin Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Suspended --> Completed
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen
Trial completion: Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma (clinicaltrials.gov) - Feb 19, 2014
P3, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
Suspended --> Completed Active, not recruiting --> Completed
- | isotretinoin / Generic mfg.
Trial completion: Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Hoag Memorial Hospital Presbyterian
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Tumor cell, Metastases: Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells (clinicaltrials.gov) - Feb 19, 2014
P2, N=5, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Enrollment open: Evaluation of Sun Protection Education for Kidney Transplant Recipients (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=181, Recruiting, Sponsor: Northwestern University
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- Enrollment change: Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin (clinicaltrials.gov) - Feb 13, 2014
P2, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=12 --> 18
- Biomarker, New P2 trial, IO biomarker, Metastases: Biomarker Correlates of Hypoxia in Metastatic Melanoma (clinicaltrials.gov) - Feb 10, 2014
P2, N=36, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Enrollment change: Cancer Mortality Affected by the Choice of Anesthetic Drugs? (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=3284, Completed, Sponsor: Enlund
N=12 --> 18 N=4500 --> 3284
- Trial completion: Cancer Mortality Affected by the Choice of Anesthetic Drugs? (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=3284, Completed, Sponsor: Enlund
N=4500 --> 3284 Active, not recruiting --> Completed
- Onureg (azacitidine oral) / BMS
Trial withdrawal, Metastases: Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy na (clinicaltrials.gov) - Feb 2, 2014
P2, N=0, Withdrawn, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Onureg (azacitidine oral) / BMS
Enrollment change, Metastases: Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy na (clinicaltrials.gov) - Feb 2, 2014
P2, N=0, Withdrawn, Sponsor: Celgene Corporation
Not yet recruiting --> Withdrawn N=80 --> 0
- Enrollment closed: Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin (clinicaltrials.gov) - Jan 13, 2014
P2, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=80 --> 0 Recruiting --> Active, not recruiting
- Veregen (sinecatechins) / Sinphar Pharma, Medigene
New P2/3 trial: Topical Green Tea Ointment in Treatment of Superficial Skin Cancer (clinicaltrials.gov) - Jan 5, 2014
P2/3, N=42, Not yet recruiting, Sponsor: Maastricht University Medical Center
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, Tumor cell, Metastases: Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells (clinicaltrials.gov) - Dec 19, 2013
P2, N=5, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=57 --> 5
- Trial termination: Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=11, Terminated, Sponsor: M.D. Anderson Cancer Center
N=57 --> 5 Active, not recruiting --> Terminated; Low accrual.
- Enrollment change: Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=11, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Low accrual. N=60 --> 11
- | Enrollment closed: A Randomized Control Trial of Sun Protection Interventions for Operating Engineers (clinicaltrials.gov) - Nov 25, 2013
P2/3, N=256, Active, not recruiting, Sponsor: University of Michigan
N=60 --> 11 Recruiting --> Active, not recruiting
- | Hiltonol (poly-ICLC) / Oncovir
Enrollment open: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (clinicaltrials.gov) - Nov 19, 2013
P2, N=20, Recruiting, Sponsor: Dr. Nina Bhardwaj
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial suspension: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=150, Suspended, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | Hiltonol (poly-ICLC) / Oncovir
New P2 trial: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (clinicaltrials.gov) - Nov 13, 2013
P2, N=20, Recruiting, Sponsor: Dr. Nina Bhardwaj
- PSMA-targeted docetaxel (BIND-014) / Pfizer
Enrollment closed, Metastases: A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Nov 11, 2013
P1, N=30, Active, not recruiting, Sponsor: BIND Therapeutics
Recruiting --> Suspended Recruiting --> Active, not recruiting
- Trial initiation date: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Initiation date: Jul 2012 --> Nov 2013
- Enrollment open: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Jul 2012 --> Nov 2013 Not yet recruiting --> Recruiting
- Trial termination: Safety Study of CALAA-01 to Treat Solid Tumor Cancers (clinicaltrials.gov) - Oct 29, 2013
P1, N=24, Terminated, Sponsor: Calando Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- Enrollment change: Safety Study of CALAA-01 to Treat Solid Tumor Cancers (clinicaltrials.gov) - Oct 29, 2013
P1, N=24, Terminated, Sponsor: Calando Pharmaceuticals
Active, not recruiting --> Terminated N=36 --> 24
- arsenic trioxide / Generic mfg.
Biomarker, Enrollment closed: Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma (clinicaltrials.gov) - Oct 15, 2013
P=N/A, N=5, Active, not recruiting, Sponsor: Stanford University
N=36 --> 24 Recruiting --> Active, not recruiting
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial suspension, Combination therapy: MEL53: Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=24, Suspended, Sponsor: University of Virginia
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Zumagev (astuprotimut-R) / GSK
Enrollment closed, Immune cell: Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (clinicaltrials.gov) - Sep 18, 2013
P0, N=27, Active, not recruiting, Sponsor: Craig L Slingluff, Jr
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion, Surgery: CRUK-LON-SINS-C7484/A2869: Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer (clinicaltrials.gov) - Sep 15, 2013
P3, N=500, Completed, Sponsor: Queen's Medical Centre
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Onureg (azacitidine oral) / BMS
New P2 trial, Metastases: Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy na (clinicaltrials.gov) - Aug 28, 2013
P2, N=0, Withdrawn, Sponsor: Celgene Corporation
- Erivedge (vismodegib) / Roche
Enrollment closed, Surgery: Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov) - Aug 27, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- sirolimus / Generic mfg.
Enrollment change: Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma (clinicaltrials.gov) - Aug 14, 2013
P2, N=43, Recruiting, Sponsor: University of Florida
Recruiting --> Active, not recruiting N=106 --> 43
- IL-12 engineered TIL / National Cancer Institute
Trial suspension, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - Aug 7, 2013
P1/2, N=31, Suspended, Sponsor: National Cancer Institute (NCI)
N=106 --> 43 Recruiting --> Suspended
- IL-12 engineered TIL / National Cancer Institute
Enrollment change, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - Aug 7, 2013
P1/2, N=31, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=103 --> 31
- | carboplatin / Generic mfg.
Enrollment change: Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck (clinicaltrials.gov) - Aug 4, 2013
P3, N=350, Recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
N=103 --> 31 N=265 --> 350
- celecoxib oral / Generic mfg.
Trial withdrawal: Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses (clinicaltrials.gov) - Jul 31, 2013
P2/3, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
N=265 --> 350 Active, not recruiting --> Withdrawn
- Trial suspension: Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=110, Suspended, Sponsor: Emory University
Active, not recruiting --> Withdrawn Recruiting --> Suspended
- Trial completion: Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation (clinicaltrials.gov) - Jun 4, 2013
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Active, not recruiting --> Completed
- | Enrollment change: Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage (clinicaltrials.gov) - Jun 2, 2013
P3, N=73, Completed, Sponsor: Institut Claudius Regaud
Active, not recruiting --> Completed N=145 --> 73
- | Trial completion: Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage (clinicaltrials.gov) - Jun 2, 2013
P3, N=73, Completed, Sponsor: Institut Claudius Regaud
N=145 --> 73 Recruiting --> Completed
- sirolimus / Generic mfg.
Enrollment open: Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma (clinicaltrials.gov) - May 6, 2013
P2, N=43, Recruiting, Sponsor: University of Florida
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination, Metastases: Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 29, 2013
P1/2, N=0, Terminated, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion: Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer (clinicaltrials.gov) - Apr 24, 2013
P1, N=0, Completed, Sponsor: National Naval Medical Center
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- capecitabine / Generic mfg.
New P2 trial, Metastases: Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin (clinicaltrials.gov) - Apr 2, 2013
P2, N=19, Recruiting, Sponsor: Stanford University
- Enrollment change: Tailored Intervention for Melanoma Patient's Families (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=553, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed N=1165 --> 553
- Trial completion: Tailored Intervention for Melanoma Patient's Families (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=553, Completed, Sponsor: Fox Chase Cancer Center
N=1165 --> 553 Active, not recruiting --> Completed
- dasatinib / Generic mfg.
Enrollment closed, Metastases: Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 17, 2013
P2, N=35, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Zelboraf (vemurafenib) / Roche
Trial termination, Metastases: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation (clinicaltrials.gov) - Mar 13, 2013
P2, N=2, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Terminated; Lack of accrual